A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity.
To determine whether a low dose (0.25 mg/0.01 mL) of intravitreal bevacizumab is effective in the treatment of type 1 retinopathy of prematurity (ROP). This prospective, noncomparative, interventional case series included all consecutive infants who received 0.25 mg/0.01 mL of intravitreal bevacizumab for type 1 ROP. Infants were followed for ROP persistence/recurrence until 90 weeks' postmenstrual age. A total of 49 eyes of 25 infants (24 bilateral and 1 unilateral) underwent intravitreal injection of a reduced dose (0.25 mg/0.01 mL) of intravitreal bevacizumab. ROP regressed in all eyes. Follow-up continued until 90 weeks' postmenstrual age and showed no recurrences of plus disease or neovascularization. All eyes treated with 0.25mg/0.01ml intravitreal bevacizumab showed complete regression, with no recurrence of plus disease or neovascularization. No safety issues were attributable to bevacizumab during the study period.